Why Pan-Cancer Immunotherapy Is a Biotech Goldmine
How tissue-agnostic therapies are expanding markets, accelerating approvals, and lowering risk across oncology portfolios
TL;DR: The smartest bets aren’t single-use. Pan-cancer drugs turn immune insight into portfolio power.
One drug can treat many cancers by targeting shared biomarkers like MSI-H or TMB, regardless of tumor location.
Pan-cancer biomarkers are found in over 20% of tumors, greatly expanding the market opportunity for a single therapy.
The FDA is enabling faster, tissue-agnostic approvals through biomarker-guided basket trials.
Immunotherapies often deliver long-lasting responses and immune memory, driving durable value.
A single pan-cancer asset can unlock multiple indications, lowering development risk and increasing return potential.
Capital is flowing into biomarker-first oncology strategies as the next generation of blockbusters emerges.
Pan-cancer (or tissue-agnostic) immunotherapies treat tumors based on shared molecular features, not the organ of origin. In practice, this means a single drug can potentially work against any cancer that carries the right biomarker. The U.S. FDA has already…
